Avonib R&D manufacturer

Ivosidenib (Ivosidenib) was developed by the American biotechnology company Agios Pharmaceuticals. Agios Pharmaceuticals is focused on developing innovative medicines to treat cancer and inherited blood disorders. The company's mission is to discover and develop novel treatments that target key metabolic pathways through a deep understanding of the principles of cellular metabolism. The successful development of ivonib as an IDH1 inhibitor represents an important development for Agios Pharmaceuticals in the field of leukemia treatment. Through continuous research and innovation, the company is committed to providing patients with more effective and safer treatment options and promoting progress in the medical field.